Skip to main content
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in:

Open Access 02-03-2022 | Parkinson Disease | Original Communication

Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinson’s disease

Authors: Carolin Gabbert, Inke R. König, Theresa Lüth, Beke Kolms, Meike Kasten, Eva-Juliane Vollstedt, Alexander Balck, Anne Grünewald, Christine Klein, Joanne Trinh

Published in: Journal of Neurology | Issue 8/2022

Login to get access

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder. Genetic modifiers, environmental factors and gene–environment interactions have been found to modify PD risk and disease progression. The objective of this study was to evaluate the association of smoking, caffeine and anti-inflammatory drugs with age at onset (AAO) in a large PD cohort. A total of 35,963 American patients with idiopathic PD (iPD) from the Fox Insight Study responded to health and lifestyle questionnaires. We compared the median AAO between different groups using the non-parametric Mann–Whitney U test. Non-parametric Spearman’s correlation was used for correlation assessments and regression analysis was used to assess interaction between variables. We found that smoking (p < 0.0001), coffee drinking (p < 0.0001) and aspirin intake (p < 0.0001) show an exploratory association with AAO in PD, that was further supported by multivariate regression models. The association of aspirin with PD AAO was replicated in another cohort (EPIPARK) (n = 237 patients with PD).
Appendix
Available only for authorised users
Literature
1.
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef
2.
3.
Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The emerging evidence of the Parkinson pandemic. J Park Dis 8:S3–S8
4.
Delamarre A, Meissner WG (2017) Epidemiology, environmental risk factors and genetics of Parkinson’s disease. Presse Med 46:175–181PubMedCrossRef
5.
Gallo V, Vineis P, Cancellieri M, Chiodini P, Barker RA, Brayne C, Pearce N, Vermeulen R, Panico S, Bueno-de-Mesquita B, Vanacore N, Forsgren L, Ramat S, Ardanaz E, Arriola L, Peterson J, Hansson O, Gavrila D, Sacerdote C, Sieri S, Kuhn T, Katzke VA, van der Schouw YT, Kyrozis A, Masala G, Mattiello A, Perneczky R, Middleton L, Saracci R, Riboli E (2019) Exploring causality of the association between smoking and Parkinson’s disease. Int J Epidemiol 48:912–925PubMed
6.
Mappin-Kasirer B, Pan H, Lewington S, Kizza J, Gray R, Clarke R, Peto R (2020) Tobacco smoking and the risk of Parkinson disease: a 65-year follow-up of 30,000 male British doctors. Neurology 94:e2132–e2138PubMedPubMedCentralCrossRef
7.
Kandinov B, Giladi N, Korczyn AD (2009) Smoking and tea consumption delay onset of Parkinson’s disease. Park Relat Disord 15:41–46CrossRef
8.
Gigante AF, Martino T, Iliceto G, Defazio G (2017) Smoking and age-at-onset of both motor and non-motor symptoms in Parkinson’s disease. Park Relat Disord 45:94–96CrossRef
9.
Martino R, Candundo H, Lieshout PV, Shin S, Crispo JAG, Barakat-Haddad C (2017) Onset and progression factors in Parkinson’s disease: a systematic review. Neurotoxicology 61:132–141PubMedCrossRef
10.
De Reuck J, De Weweire M, Van Maele G, Santens P (2005) Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson’s disease. J Neurol Sci 231:35–39PubMedCrossRef
11.
Wijeyekoon R, Suriyakumara V, Gamage R, Fernando T, Jayasuriya A, Amarasinghe D, Gunasekara H, Sirisena D, Amaratunga D, Muthukuda C, Barker RA, Williams-Gray C, De Silva R (2017) Associations between lifestyle factors and Parkinson’s disease in an Urban Sri Lankan Clinic Study. Int Arch Med. https://​doi.​org/​10.​3823/​2516CrossRefPubMed
12.
Yahalom G, Rigbi A, Israeli-Korn S, Krohn L, Rudakou U, Ruskey JA, Benshimol L, Tsafnat T, Gan-Or Z, Hassin-Baer S, Greenbaum L (2020) Age at onset of Parkinson’s disease among Ashkenazi Jewish patients: contribution of environmental factors, LRRK2 p. G2019S and GBA p.N370S mutations. J Park Dis 10:1123–1132
13.
Luth T, Konig IR, Grunewald A, Kasten M, Klein C, Hentati F, Farrer M, Trinh J (2020) Age at onset of LRRK2 p.Gly2019Ser is related to environmental and lifestyle factors. Mov Disord 35:1854–1858PubMedCrossRef
14.
Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001) Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 50:56–63PubMedCrossRef
15.
Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA (2000) Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: a case-control study. Neurology 55:1350–1358PubMedCrossRef
16.
Tan EK, Chua E, Fook-Chong SM, Teo YY, Yuen Y, Tan L, Zhao Y (2007) Association between caffeine intake and risk of Parkinson’s disease among fast and slow metabolizers. Pharmacogenet Genom 17:1001–1005CrossRef
17.
Gigante AF, Asabella AN, Iliceto G, Martino T, Ferrari C, Defazio G, Rubini G (2018) Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson’s disease. Neurol Sci 39:551–555PubMedCrossRef
18.
Wahner AD, Bronstein JM, Bordelon YM, Ritz B (2007) Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69:1836–1842PubMedCrossRef
19.
Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann Neurol 58:963–967PubMedCrossRef
20.
San Luciano M, Tanner CM, Meng C, Marras C, Goldman SM, Lang AE, Tolosa E, Schule B, Langston JW, Brice A, Corvol JC, Goldwurm S, Klein C, Brockman S, Berg D, Brockmann K, Ferreira JJ, Tazir M, Mellick GD, Sue CM, Hasegawa K, Tan EK, Bressman S, Saunders-Pullman R, Michael JFFLCC (2020) Nonsteroidal anti-inflammatory use and LRRK2 Parkinson’s disease penetrance. Mov Disord 35:1755–1764PubMedCrossRef
21.
Smolensky L, Amondikar N, Crawford K, Neu S, Kopil CM, Daeschler M, Riley L, Brown E, Toga AW, Tanner C (2020) Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson’s disease. Sci Data 7:67PubMedPubMedCentralCrossRef
22.
Kasten M, Hagenah J, Graf J, Lorwin A, Vollstedt EJ, Peters E, Katalinic A, Raspe H, Klein C (2013) Cohort profile: a population-based cohort to study non-motor symptoms in parkinsonism (EPIPARK). Int J Epidemiol 42:128–128kPubMedCrossRef
23.
Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 15:1257–1272PubMedCrossRef
24.
Auriel E, Regev K, Korczyn AD (2014) Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. Handb Clin Neurol 119:577–584PubMedCrossRef
25.
26.
Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, Saint-Hilaire M, Wilk JB, Volcjak J, Maher JE, Feldman RG, Guttman M, Lew M, Waters CH, Schuman S, Suchowersky O, Lafontaine AL, Labelle N, Vieregge P, Pramstaller PP, Klein C, Hubble J, Reider C, Growdon J, Watts R, Montgomery E, Baker K, Singer C, Stacy M, Myers RH (2002) Epidemiologic study of 203 sibling pairs with Parkinson’s disease: the GenePD study. Neurology 58:79–84PubMedCrossRef
27.
Wilk JB, Lash TL (2007) Risk factor studies of age-at-onset in a sample ascertained for Parkinson disease affected sibling pairs: a cautionary tale. Emerg Themes Epidemiol 4:1PubMedPubMedCentralCrossRef
28.
Grandinetti A, Morens DM, Reed D, MacEachern D (1994) Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease. Am J Epidemiol 139:1129–1138PubMedCrossRef
29.
Greenbaum L, Rigbi A, Lipshtat N, Cilia R, Tesei S, Asselta R, Djaldetti R, Goldwurm S, Lerer B (2013) Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson’s disease age at onset: gene and smoking status interaction. Park Relat Disord 19:72–76CrossRef
30.
Haack DG, Baumann RJ, McKean HE, Jameson HD, Turbek JA (1981) Nicotine exposure and Parkinson disease. Am J Epidemiol 114:191–200PubMedCrossRef
31.
Jimenez-Jimenez FJ, Mateo D, Gimenez-Roldan S (1992) Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson’s disease: a case-control study. Mov Disord 7:339–344PubMedCrossRef
32.
Kuopio AM, Marttila RJ, Helenius H, Rinne UK (1999) Environmental risk factors in Parkinson’s disease. Mov Disord 14:928–939PubMedCrossRef
33.
Martinez-Rumayor A, Arrieta O, Sotelo J, Garcia E (2009) Female gender but not cigarette smoking delays the onset of Parkinson’s disease. Clin Neurol Neurosurg 111:738–741PubMedCrossRef
34.
Mayeux R, Tang MX, Marder K, Cote LJ, Stern Y (1994) Smoking and Parkinson’s disease. Mov Disord 9:207–212PubMedCrossRef
35.
Neshige S, Ohshita T, Neshige R, Maruyama H (2021) Influence of current and previous smoking on current phenotype in Parkinson’s disease. J Neurol Sci 427:117534PubMedCrossRef
36.
Papapetropoulos S, Singer C, Villar JM, Gonzalez J, Mash DC (2005) Does cigarette smoking provide clinically significant neuroprotection among patients diagnosed with Parkinson’s disease? Mov Disord 20:641–642PubMedCrossRef
37.
Scott WK, Zhang F, Stajich JM, Scott BL, Stacy MA, Vance JM (2005) Family-based case-control study of cigarette smoking and Parkinson disease. Neurology 64:442–447PubMedCrossRef
38.
Weisskopf MG, Grodstein F, Ascherio A (2007) Smoking and cognitive function in Parkinson’s disease. Mov Disord 22:660–665PubMedCrossRef
39.
40.
Cho BH, Choi SM, Kim JT, Kim BC (2018) Association of coffee consumption and non-motor symptoms in drug-naive, early-stage Parkinson’s disease. Park Relat Disord 50:42–47CrossRef
41.
Paul KC, Chuang YH, Shih IF, Keener A, Bordelon Y, Bronstein JM, Ritz B (2019) The association between lifestyle factors and Parkinson’s disease progression and mortality. Mov Disord 34:58–66PubMedPubMedCentralCrossRef
42.
Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674–2679PubMedCrossRef
43.
Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J (2007) Coffee and tea consumption and the risk of Parkinson’s disease. Mov Disord 22:2242–2248PubMedCrossRef
44.
Chahine LM, Chin I, Caspell-Garcia C, Standaert DG, Brown E, Smolensky L, Arnedo V, Daeschler D, Riley L, Korell M, Dobkin R, Amondikar N, Gradinscak S, Shoulson I, Dean M, Kwok K, Cannon P, Marek K, Kopil C, Tanner CM, Marrason C (2020) Comparison of an online-only Parkinson’s disease research cohort to cohorts assessed in person. J Park Dis 10:677–691
45.
Dobkin RD, Amondikar N, Kopil C, Caspell-Garcia C, Brown E, Chahine LM, Marras C, Dahodwala N, Mantri S, Standaert DG, Dean M, Shoulson I, Marek K, Katz A, Korell M, Riley L, Tanner CM, Fox Insight S (2020) Innovative recruitment strategies to increase diversity of participation in Parkinson’s disease research: the Fox Insight Cohort Experience. J Park Dis 10:665–675. https://​doi.​org/​10.​3233/​JPD-191901CrossRef
Metadata
Title
Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinson’s disease
Authors
Carolin Gabbert
Inke R. König
Theresa Lüth
Beke Kolms
Meike Kasten
Eva-Juliane Vollstedt
Alexander Balck
Anne Grünewald
Christine Klein
Joanne Trinh
Publication date
02-03-2022
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 8/2022
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-022-11041-x

Other articles of this Issue 8/2022

Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study

GGC repeat expansions in NOTCH2NLC causing a phenotype of lower motor neuron syndrome

Acute posterior circulation toxic encephalopathy following wasp sting: a case report on a novel syndrome

Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients

Botulinum toxin treatment improves dysphagia in patients with oculopharyngeal muscular dystrophy and sporadic inclusion body myositis

MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions

How can you integrate PET into your practice? (Link opens in a new window)

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Register your interest

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video
Image Credits